Eribulin With or Without Trastuzumab-biosimilar in Patients With HER2-overexpressed Recurrent or Stage IV Breast Cancer
Status:
Recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
Optimal salvage treatment for HER2-positive breast cancer after trastuzumab and T-DM1 failure
still remains to be established. We would like to investigate the efficacy and safety of
combination chemotherapy of eribulin and trastuzumab as salvage treatment for HER2-Positive
breast cancer after exposure to trastuzumab and T-DM1